Multiple expressions of lymphatic markers and morphological evolution of newly formed lymphatics in lymphangioma and lymph node lymphangiogenesis
- PMID: 20382171
- DOI: 10.1016/j.mvr.2010.04.002
Multiple expressions of lymphatic markers and morphological evolution of newly formed lymphatics in lymphangioma and lymph node lymphangiogenesis
Abstract
The rapid evolution of reliable technology combined with increasing number of specific markers for lymphatic endothelial cells (LECs) facilitates the investigation of lymphangiogenesis in developing and diseased tissues. Here, we injected incomplete Freund's adjuvant (IFA) peritoneally into BALB/c and nonobese diabetic (NOD) mice to induce lymphangioma and found atypical lymphatic accumulations with intervening fibrous tissue and lymphoid aggregates. Lymphatic markers, LYVE-1 and podoplanin, were used to specifically define the morphological features of the neoplastic lymphatics. The NOD mice (affected by an autoimmune disorder) had fewer and smaller lymphangiomas than the BALB/c mice. Injection of IFA in the footpad skin of the mice also disturbed draining regional lymph node lymphangiogenesis and caused enlargement of popliteal lymph nodes. Molecular analyses of the LECs indicated potential interventions for lymphangioma through vascular endothelial growth factor (VEGF)-A/-C/-D and their receptors, VEGF receptors-2/-3, and Prox-1 signaling pathways. These findings represent an important link between multiple factors and lymphatic disorders.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Investigation of intratumoural and peritumoural lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours.Int J Exp Pathol. 2007 Aug;88(4):257-70. doi: 10.1111/j.1365-2613.2007.00532.x. Int J Exp Pathol. 2007. PMID: 17696907 Free PMC article.
-
Similarities and differences of human and experimental mouse lymphangiomas.Dev Dyn. 2007 Oct;236(10):2952-61. doi: 10.1002/dvdy.21298. Dev Dyn. 2007. PMID: 17879316
-
Podoplanin+ tumor lymphatics are rate limiting for breast cancer metastasis.PLoS Biol. 2018 Dec 28;16(12):e2005907. doi: 10.1371/journal.pbio.2005907. eCollection 2018 Dec. PLoS Biol. 2018. PMID: 30592710 Free PMC article.
-
Molecular control of lymphatic metastasis.Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Ann N Y Acad Sci. 2008. PMID: 18519975 Review.
-
Molecular and cellular mechanisms of lymphangiogenesis.Eur J Surg Oncol. 2005 Mar;31(2):117-21. doi: 10.1016/j.ejso.2004.08.015. Eur J Surg Oncol. 2005. PMID: 15698725 Review.
Cited by
-
Cross-sectional study comparing different therapeutic modalities for cystic lymphangiomas in children.Clinics (Sao Paulo). 2014 Aug;69(8):505-8. doi: 10.6061/clinics/2014(08)01. Clinics (Sao Paulo). 2014. PMID: 25141107 Free PMC article.
-
Rapamycin inhibition of CFA-induced lymphangiogenesis in PLN is independent of mast cells.Mol Biol Rep. 2014;41(4):2217-28. doi: 10.1007/s11033-014-3073-1. Epub 2014 Jan 14. Mol Biol Rep. 2014. PMID: 24420861
-
Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel). 2025 May 19;18(5):751. doi: 10.3390/ph18050751. Pharmaceuticals (Basel). 2025. PMID: 40430568 Free PMC article. Review.
-
Systemic generalised lymphangiomatosis: unknown aetiology and a challenge to treat.BMJ Case Rep. 2021 Jan 18;14(1):e237331. doi: 10.1136/bcr-2020-237331. BMJ Case Rep. 2021. PMID: 33462010 Free PMC article.
-
Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis.Cell Mol Life Sci. 2012 Mar;69(6):897-914. doi: 10.1007/s00018-011-0848-6. Epub 2011 Oct 8. Cell Mol Life Sci. 2012. PMID: 21984600 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous